Skip to main content
Erschienen in: Documenta Ophthalmologica 2/2013

01.04.2013 | Original Research Article

Extrafoveal changes following intravitreal bevacizumab injections for macular edema secondary to branch retinal vein occlusion: an mfERG and OCT study

verfasst von: Saemi Park, In Hwan Cho, Tae Kwann Park, Woo Ho Nam, Young-Hoon Ohn

Erschienen in: Documenta Ophthalmologica | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the functional and structural changes of extrafoveal macula after intravitreal bevacizumab (IVB) injection in patients with macular edema due to branch retinal vein occlusion (BRVO) using multifocal electroretinogram (mfERG) and optical coherence tomography (OCT).

Methods

A total of 19 eyes of 19 patients with macular edema due to BRVO received three consecutive IVB injections with a 6-week interval. Spectral domain optical coherence tomography (SD-OCT), mfERG, and fluorescein angiography (FA) were performed at baseline. The macular area was divided into four quadrants (Q1–Q4) based on FA. The mean retinal thickness (MRT) and mfERG parameters in each of the four quadrants were measured at baseline and 4 weeks after the third injection.

Results

The MRT in the four quadrants improved significantly after IVB injections (p < 0.01 for Q1 and Q2, p < 0.05 for Q3 and Q4) compared to baseline. The significant improvements in mfERG responses were seen in Q1 and Q2. In Q1, there were 68 and 56 % improvement in N1 and P1 amplitude, respectively (p < 0.01). N1 and P1 amplitude in Q2 increased significantly by 43 and 46 %, respectively, compared to baseline (p < 0.05). The MRT and P1 amplitude were significantly correlated at baseline in Q1 and Q2, but no significant correlations were found after three IVB injections.

Conclusions

The injection of IVB improved functional and structural outcomes in the primarily affected half of the extrafoveal macula effectively. The measurements of structural and functional changes using mfERG and OCT may be appropriate for monitoring the effects of IVB injection in BRVO patients.
Literatur
1.
Zurück zum Zitat Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114:1243–1247PubMedCrossRef Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114:1243–1247PubMedCrossRef
2.
Zurück zum Zitat The Branch Retinal Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271–282 The Branch Retinal Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271–282
3.
Zurück zum Zitat Michels RG, Gass JD (1974) The natural course of retinal vein obstruction. Trans Am Acad Ophthalmol Otolaryngol 78:OPI166–OPI177 Michels RG, Gass JD (1974) The natural course of retinal vein obstruction. Trans Am Acad Ophthalmol Otolaryngol 78:OPI166–OPI177
4.
Zurück zum Zitat Finkelstein D (1992) Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 110:1427–1434PubMedCrossRef Finkelstein D (1992) Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 110:1427–1434PubMedCrossRef
5.
Zurück zum Zitat Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33:111–131PubMedCrossRef Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33:111–131PubMedCrossRef
6.
Zurück zum Zitat Spaide RF, Lee JK, Klancnik JK Jr, Gross NE (2003) Optical coherence tomography of branch retinal vein occlusion. Retina 23:343–347PubMedCrossRef Spaide RF, Lee JK, Klancnik JK Jr, Gross NE (2003) Optical coherence tomography of branch retinal vein occlusion. Retina 23:343–347PubMedCrossRef
7.
Zurück zum Zitat Parodi MB, Di Stefano G, Ravalico G (2008) Grid laser treatment for exudative retinal detachment secondary to ischemic branch retinal vein occlusion. Retina 28:97–102PubMedCrossRef Parodi MB, Di Stefano G, Ravalico G (2008) Grid laser treatment for exudative retinal detachment secondary to ischemic branch retinal vein occlusion. Retina 28:97–102PubMedCrossRef
8.
Zurück zum Zitat Christofferson NL, Larsen M (1999) Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 106:2054–2062CrossRef Christofferson NL, Larsen M (1999) Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 106:2054–2062CrossRef
9.
Zurück zum Zitat Krieschbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92:518–522CrossRef Krieschbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92:518–522CrossRef
10.
Zurück zum Zitat Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch vein occlusion. Retina 27:419–425PubMedCrossRef Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch vein occlusion. Retina 27:419–425PubMedCrossRef
11.
Zurück zum Zitat Figueroa MS, Contreras I, Noval S, Arruabarrena C (2010) Results of Bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 94:1052–1056PubMedCrossRef Figueroa MS, Contreras I, Noval S, Arruabarrena C (2010) Results of Bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 94:1052–1056PubMedCrossRef
12.
Zurück zum Zitat Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and eletrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606PubMedCrossRef Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and eletrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606PubMedCrossRef
13.
Zurück zum Zitat Matt G, Sacu S, Buehl W, Ahlers C, Dunavoelgyi R, Pruente C, Schmidt-Erfurth U (2011) Comparison of retinal thickness values and segmentation performance of different OCT devices in acute branch retinal vein occlusion. Eye 25:511–518PubMedCrossRef Matt G, Sacu S, Buehl W, Ahlers C, Dunavoelgyi R, Pruente C, Schmidt-Erfurth U (2011) Comparison of retinal thickness values and segmentation performance of different OCT devices in acute branch retinal vein occlusion. Eye 25:511–518PubMedCrossRef
14.
Zurück zum Zitat Hood DC, Bach M, Brigell M, Keating D, Kondo M, Lyons JS, Marmor MF, McCulloch DL, Palmowski-Wolfe AM, International Society for Clinical Electrophysiology of Vision (2012) ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol 124:1–13PubMedCrossRef Hood DC, Bach M, Brigell M, Keating D, Kondo M, Lyons JS, Marmor MF, McCulloch DL, Palmowski-Wolfe AM, International Society for Clinical Electrophysiology of Vision (2012) ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol 124:1–13PubMedCrossRef
15.
Zurück zum Zitat Arnarsson A, Stefánsson E (2000) Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 41:877–879PubMed Arnarsson A, Stefánsson E (2000) Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 41:877–879PubMed
16.
Zurück zum Zitat Silva RM, Faria de Abreu JR, Cunha-Vaz JG (1995) Blood-retina barrier in acute retinal branch vein occlusion. Graefes Arch Clin Exp Ophthalmol 233:721–726PubMedCrossRef Silva RM, Faria de Abreu JR, Cunha-Vaz JG (1995) Blood-retina barrier in acute retinal branch vein occlusion. Graefes Arch Clin Exp Ophthalmol 233:721–726PubMedCrossRef
17.
Zurück zum Zitat Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Jian K, Sakamoto I, Nakano K, Yamashita H, Minamoto A, Mishima HK (2005) Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 140:256–261PubMedCrossRef Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Jian K, Sakamoto I, Nakano K, Yamashita H, Minamoto A, Mishima HK (2005) Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 140:256–261PubMedCrossRef
18.
Zurück zum Zitat Noma H, Funatsu H, Sakata K, Harino S, Nagaoka T, Mimura T, Sone T, Hori S (2009) Macular microcirculation and macular oedema in branch retinal vein occlusion. Br J Ophthalmol 93:630–633PubMedCrossRef Noma H, Funatsu H, Sakata K, Harino S, Nagaoka T, Mimura T, Sone T, Hori S (2009) Macular microcirculation and macular oedema in branch retinal vein occlusion. Br J Ophthalmol 93:630–633PubMedCrossRef
19.
Zurück zum Zitat Moschos MM, Moschos M (2008) Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol 116:147–152PubMedCrossRef Moschos MM, Moschos M (2008) Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol 116:147–152PubMedCrossRef
20.
Zurück zum Zitat Torres-Soriano ME, Cubas-Lorenzo V, García-Aguirre G, Hernández-Rojas M, Kon-Jara V, Díaz-Rubio J, Fromow-Guerra J, Quiroz-Mercado H, Jiménez-Sierra JM (2012) Multifocal electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 32:972–976PubMedCrossRef Torres-Soriano ME, Cubas-Lorenzo V, García-Aguirre G, Hernández-Rojas M, Kon-Jara V, Díaz-Rubio J, Fromow-Guerra J, Quiroz-Mercado H, Jiménez-Sierra JM (2012) Multifocal electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 32:972–976PubMedCrossRef
21.
Zurück zum Zitat Shetty R, Pai SA, Vincent A, Shetty N, Narayana KM, Sinha B, Shetty BK (2008) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 116:129–135PubMedCrossRef Shetty R, Pai SA, Vincent A, Shetty N, Narayana KM, Sinha B, Shetty BK (2008) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 116:129–135PubMedCrossRef
22.
Zurück zum Zitat Pedersen KB, Møller F, Sjølie AK, Andréasson S (2010) Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration. Retina 30:1025–1033PubMedCrossRef Pedersen KB, Møller F, Sjølie AK, Andréasson S (2010) Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration. Retina 30:1025–1033PubMedCrossRef
23.
Zurück zum Zitat Hvarfner C, Andreasson S, Larsson J (2006) Multifocal electroretinography and fluorescein angiography in retinal vein occlusion. Retina 26:292–296PubMedCrossRef Hvarfner C, Andreasson S, Larsson J (2006) Multifocal electroretinography and fluorescein angiography in retinal vein occlusion. Retina 26:292–296PubMedCrossRef
24.
Zurück zum Zitat Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Doc Ophthalmol 114:37–44PubMedCrossRef Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Doc Ophthalmol 114:37–44PubMedCrossRef
25.
Zurück zum Zitat Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U (2009) Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50:1025–1032PubMedCrossRef Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U (2009) Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50:1025–1032PubMedCrossRef
26.
Zurück zum Zitat Silva MF, Mateus C, Reis A, Nunes S, Fonseca P, Castelo-Branco M (2010) Asymmetry of visual sensory mechanisms: electrophysiological, structural, and psychophysical evidences. J Vis 10:1–11CrossRef Silva MF, Mateus C, Reis A, Nunes S, Fonseca P, Castelo-Branco M (2010) Asymmetry of visual sensory mechanisms: electrophysiological, structural, and psychophysical evidences. J Vis 10:1–11CrossRef
27.
Zurück zum Zitat Vincent A, Shetty R, Devi SA, Kurian MK, Balu R, Shetty B (2010) Functional involvement of cone photoreceptors in advanced glaucoma: a multifocal electroretinogram study. Doc Ophthalmol 121:21–27PubMedCrossRef Vincent A, Shetty R, Devi SA, Kurian MK, Balu R, Shetty B (2010) Functional involvement of cone photoreceptors in advanced glaucoma: a multifocal electroretinogram study. Doc Ophthalmol 121:21–27PubMedCrossRef
28.
Zurück zum Zitat Grover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271PubMedCrossRef Grover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271PubMedCrossRef
29.
Zurück zum Zitat Grover S, Murthy RK, Brar VS, Chalam KV (2010) Comparison of retinal thickness in normal eyes using stratus and spectralis optical coherence tomography. Invest Ophthalmol Vis Sci 51:2644–2647PubMedCrossRef Grover S, Murthy RK, Brar VS, Chalam KV (2010) Comparison of retinal thickness in normal eyes using stratus and spectralis optical coherence tomography. Invest Ophthalmol Vis Sci 51:2644–2647PubMedCrossRef
Metadaten
Titel
Extrafoveal changes following intravitreal bevacizumab injections for macular edema secondary to branch retinal vein occlusion: an mfERG and OCT study
verfasst von
Saemi Park
In Hwan Cho
Tae Kwann Park
Woo Ho Nam
Young-Hoon Ohn
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Documenta Ophthalmologica / Ausgabe 2/2013
Print ISSN: 0012-4486
Elektronische ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-012-9367-5

Weitere Artikel der Ausgabe 2/2013

Documenta Ophthalmologica 2/2013 Zur Ausgabe

EditorialNotes

Editor’s comment

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.